search
Back to results

Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia

Primary Purpose

Leg Ulcer, Diabetic Foot, Gangrene

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
BM-ECs and PRPE
BM-ECs
Sponsored by
South China Research Center for Stem Cell and Regenerative Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leg Ulcer

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Limb ischemia patients(e.g. arteriosclerosis obliterans,diabetic critical limb ischemia, thromboangitis obliterans)

  1. 18 Years to 80 Years (Adult, Senior);
  2. Have ability to understand and comply with the study requirements, and provide the written informed consent prior to any procedures ;
  3. Patient meets at least one of the following diagnostic criteria for the index limb:

    1. ABI<0.7mmHg
    2. TcpO2 <40 mm Hg
    3. Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization;
  4. Have no improvement after conservative treatment and are not suitable for surgical bypass surgery because no outflow tract of diseased vessel can be found by imaging;
  5. Despite having good outflow artery, but the elderly and frail patients can also not tolerate revascularization or interventional surgery;
  6. Unlikelihood of major amputation of the leg during the next 12 months;
  7. Expected life span more than 2 years.

Exclusion Criteria:

  1. Pregnant or lactating;
  2. Diabetics with poorly controlled blood glucose levels (defined as HbA1c>7% and/or proliferative retinopathy);
  3. Patients with decompensated cardiac, renal or liver disease;
  4. Patients with confirmed malignant tumor;
  5. Subjects are with serious heart, liver, kidney and lung failure or under poor general condition that are inability to undergo bone marrow harvesting and transplantation;
  6. Known or suspected disease of the immune system or osteomyelitis;
  7. Inability to sign informed consent form and to comply with the schedule of the study;
  8. There has reason to suspect that the patient is forced to join the study;
  9. Any other condition, in the opinion of the investigator, would render the patient unsuitable for the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    BM-ECs and PRPE

    BM-ECs

    Arm Description

    Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).

    Intramuscular injection of bone marrow derived endothelial cells only.

    Outcomes

    Primary Outcome Measures

    Survival without major amputation

    Secondary Outcome Measures

    Perfusion rate in treated tissue by measure of ankle-brachial index (ABI)
    Perfusion rate in treated tissue by transcutaneous PO2 (TcPO2)
    Perfusion rate in treated tissue by digital subtraction angiography (DSA)
    wound size
    wound stage
    Pain intensity
    Pain intensity using Visual Analogue Scale
    Thermography

    Full Information

    First Posted
    November 23, 2016
    Last Updated
    December 13, 2016
    Sponsor
    South China Research Center for Stem Cell and Regenerative Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02993809
    Brief Title
    Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2018 (undefined)
    Primary Completion Date
    December 2019 (Anticipated)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    South China Research Center for Stem Cell and Regenerative Medicine

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The intent of this clinical study is to evaluate the safety of the injection composed of autologous bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE) for the treatment of critical limb ischemia.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Leg Ulcer, Diabetic Foot, Gangrene, Peripheral Vascular Disease, Ischemia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    BM-ECs and PRPE
    Arm Type
    Experimental
    Arm Description
    Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
    Arm Title
    BM-ECs
    Arm Type
    Active Comparator
    Arm Description
    Intramuscular injection of bone marrow derived endothelial cells only.
    Intervention Type
    Biological
    Intervention Name(s)
    BM-ECs and PRPE
    Intervention Type
    Biological
    Intervention Name(s)
    BM-ECs
    Primary Outcome Measure Information:
    Title
    Survival without major amputation
    Time Frame
    6 months after implantation
    Secondary Outcome Measure Information:
    Title
    Perfusion rate in treated tissue by measure of ankle-brachial index (ABI)
    Time Frame
    Within 6 months after implantation
    Title
    Perfusion rate in treated tissue by transcutaneous PO2 (TcPO2)
    Time Frame
    Within 6 months after implantation
    Title
    Perfusion rate in treated tissue by digital subtraction angiography (DSA)
    Time Frame
    Within 6 months after implantation
    Title
    wound size
    Time Frame
    Within 6 months after implantation
    Title
    wound stage
    Time Frame
    Within 6 months after implantation
    Title
    Pain intensity
    Description
    Pain intensity using Visual Analogue Scale
    Time Frame
    Within 6 months after implantation
    Title
    Thermography
    Time Frame
    Within 6 months after implantation

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Limb ischemia patients(e.g. arteriosclerosis obliterans,diabetic critical limb ischemia, thromboangitis obliterans) 18 Years to 80 Years (Adult, Senior); Have ability to understand and comply with the study requirements, and provide the written informed consent prior to any procedures ; Patient meets at least one of the following diagnostic criteria for the index limb: ABI<0.7mmHg TcpO2 <40 mm Hg Or, nonhealing ulcer due to local arterial compromise with no opportunity for revascularization; Have no improvement after conservative treatment and are not suitable for surgical bypass surgery because no outflow tract of diseased vessel can be found by imaging; Despite having good outflow artery, but the elderly and frail patients can also not tolerate revascularization or interventional surgery; Unlikelihood of major amputation of the leg during the next 12 months; Expected life span more than 2 years. Exclusion Criteria: Pregnant or lactating; Diabetics with poorly controlled blood glucose levels (defined as HbA1c>7% and/or proliferative retinopathy); Patients with decompensated cardiac, renal or liver disease; Patients with confirmed malignant tumor; Subjects are with serious heart, liver, kidney and lung failure or under poor general condition that are inability to undergo bone marrow harvesting and transplantation; Known or suspected disease of the immune system or osteomyelitis; Inability to sign informed consent form and to comply with the schedule of the study; There has reason to suspect that the patient is forced to join the study; Any other condition, in the opinion of the investigator, would render the patient unsuitable for the study.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Xuetao Pei, M.D., Ph.D
    Phone
    8610-68164807
    Email
    AMMS0906@163.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Fang Fang, Ph.D
    Phone
    8620-89199011
    Email
    fangfang@scrm.org.cn

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes

    Learn more about this trial

    Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia

    We'll reach out to this number within 24 hrs